You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PD-1(L1)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Non Small Cell Lung Cancer Recurrent Trial (Toripalimab, Anlotinib and Chemotherapy)

Not yet recruiting
  • Non Small Cell Lung Cancer Recurrent
  • Toripalimab, Anlotinib and Chemotherapy
  • (no location specified)
Apr 24, 2023

Extensive-Stage Small Cell Lung Cancer Trial in Beijing (Surufatinib, Anti-PD-1/L1)

Not yet recruiting
  • Extensive-Stage Small Cell Lung Cancer
  • Beijing, China
    Chinese PLA General Hospital
Aug 18, 2022

Solid Tumor Trial (IN10018, Nab-paclitaxel, Tislelizumab)

Not yet recruiting
  • Solid Tumor
  • (no location specified)
Aug 1, 2023

Lung Cancer Trial (Centipeda minima+PD-1/PD-L1 inhibitor, PD-1/PD-L1 inhibitor)

Not yet recruiting
  • Lung Cancer
  • Centipeda minima+PD-1/PD-L1 inhibitor
  • PD-1/PD-L1 inhibitor
  • (no location specified)
Feb 17, 2023

irAE Prediction of Anti-PD-1/L1 in Lung Cancer

Recruiting
  • Immune Checkpoint Inhibitors
  • Lung Cancer
    • Beijing, China
      Peking Union Medical College Hospital
    Mar 31, 2022

    Advanced Solid Tumor Trial in Beijing (Inosine 0.2g orally 3 times/day, PD-1/PD-L1 inhibitor ,chemo/targeting)

    Completed
    • Advanced Solid Tumor
    • Inosine 0.2g orally 3 times/day
    • PD-1/PD-L1 inhibitor ,chemotherapy/targeting
    • Beijing, Beijing, China
      Qin li
    Mar 30, 2023

    Digestive System Cancers Trial in Beijing (KN046, Regorafenib, Apatinib)

    Recruiting
    • Digestive System Cancers
    • Beijing, China
      Peking University Cancer Hospital
    Oct 25, 2023

    Combined Statin and PD-1/PD-L1 Inhibitors in Treating Non-small

    Recruiting
    • Lung Cancer
    • Yiwu, Zhejiang, China
      The Fourth Affiliated Hospital of Zhejiang University
    Dec 16, 2022

    NSCLC Trial in Wuhan (Camrelizumab, Apatinib, Docetaxel injection)

    Recruiting
    • Non-Small Cell Lung Cancer
    • Wuhan, Hubei, China
      Zhongnan Hospital of Wuhan University
    Apr 29, 2022

    Glioblastoma Trial (Bevacizumab, PD-L1 t-haNK, N-803)

    Not yet recruiting
    • Glioblastoma
    • (no location specified)
    Sep 25, 2023

    Advanced Non Small Cell Lung Cancer Trial ([18F]F-AraG)

    Not yet recruiting
    • Advanced Non Small Cell Lung Cancer
    • (no location specified)
    Oct 24, 2023

    Advanced Solid Tumor, Refractory Tumor Trial in Suzhou (Thymalfasin, Radiotherapy, PD-1/PD-L1 inhibitor)

    Recruiting
    • Advanced Solid Tumor
    • Refractory Tumor
    • Suzhou, China
      The Second Affiliated Hospital of SchoowUniversity
    Mar 29, 2023

    High PD-L1 Expressing NSCLC Patients Treated With PD-1/PD-L1

    Suspended
    • NSCLC Stage IV
    • NSCLC, Stage IIIC
    • Primary Immune Response (PIR) test by Biodesix, Inc.
    • San Carlos, California
    • +1 more
    Jan 26, 2023

    Hepatocellular Carcinoma Trial (PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE)

    Recruiting
    • Hepatocellular Carcinoma
    • PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab
    • TACE
    • Nanjing, China
    • +1 more
    Dec 28, 2022

    Small Cell Lung Cancer Extensive Stage Trial in Jinan, Tianjin, Zhengzhou (IN10018, Tislelizumab, Carboplatin)

    Not yet recruiting
    • Small Cell Lung Cancer Extensive Stage
    • Jinan, China
    • +2 more
    Sep 10, 2023

    Hepatocellular Carcinoma Trial in Shanghai (Anti-PD-1/PD-L1, S-Adenosyl-Methionine)

    Recruiting
    • Hepatocellular Carcinoma
    • Shanghai, China
      Zhongshan Hospital Fudan university
    Jan 31, 2023

    Advanced Lung Carcinoma Trial in Beijing (LK101 injection (personlized neoantigen pulsed DC vaccine ), Pembrolizumab,

    Recruiting
    • Advanced Lung Carcinoma
    • LK101 injection (personlized neoantigen pulsed DC vaccine )
    • +2 more
    • Beijing, Beijing, China
      Cancer hospital Chinese Academy of Medical Sciences
    May 23, 2023

    Biliary Tract Cancer, Candonilimab, Claudin 18.2 Trial in Shanghai (cardonilizumab, LM-302)

    Recruiting
    • Biliary Tract Cancer
    • +2 more
    • Shanghai, China
      Zhongshan hospital, Fudan University
    Aug 12, 2023

    Urothelial Carcinoma Trial in Worldwide (Zilovertamab vedotin)

    Recruiting
    • Urothelial Carcinoma
    • Zilovertamab vedotin
    • Cleveland, Ohio
    • +11 more
    Jan 25, 2023

    Hepatocellular Carcinoma Trial (PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab, TACE)

    Recruiting
    • Hepatocellular Carcinoma
    • PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab
    • TACE
    • Nanjing, China
    • +1 more
    Dec 28, 2022

    Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression = 1% and an STK11

    Recruiting
    • Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation
    • Montpellier, France
    • +7 more
    Dec 19, 2022

    Solid Tumor Trial (BS006 Injection)

    Not yet recruiting
    • Solid Tumor
    • BS006 Injection
    • (no location specified)
    Jul 3, 2023

    Advanced Non-squamous Non-small-cell Lung Cancer, Recurrent Non-Squamous NSCLC, Metastatic Non-squamous Non Small Cell Lung

    Not yet recruiting
    • Advanced Non-squamous Non-small-cell Lung Cancer
    • +2 more
    • Beijing, Beijing, China
      Peking University First Hospital Ethics Committee
    Sep 10, 2023

    Advanced Solid Tumor Trial in Chengdu (Dual-targeting CLDN18.2 and PD-L1 CAR-T cells)

    Not yet recruiting
    • Advanced Solid Tumor
    • Dual-targeting CLDN18.2 and PD-L1 CAR-T cells
    • Chengdu, Sichuan, China
      West China Hospital, Sichuan University
    Oct 9, 2023

    Advanced Solid Tumors, Metastatic Solid Tumors Trial in Lyon (NP137, anti-PD-1/PD-L1)

    Recruiting
    • Advanced Solid Tumors
    • Metastatic Solid Tumors
    • Lyon, France
      Centre Léon Bérard
    Nov 30, 2022